SCHEMBL7112604

SCHEMBL7112604

Cc1ccccc1-c1cc(Cl)ncc1C(=O)NCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
HPGD P15428 4/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPK1 P28482 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NR3C1 P04150 1/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
PPARG P37231 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HSP90AA1 P07900 2/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
HSP90AB1 P08238 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905344 0.85 GPBAR1 (0.50) L3MBTL1KMT2AHTTGAACYP1A2
SCHEMBL7112402 0.81 GPBAR1 (0.53) HPGDKDM4EALDH1A1KMT2AGAA
SCHEMBL7110261 0.79 GPBAR1 (0.47) ALDH1A1MEN1KMT2AHTTSMN1; SMN2
SCHEMBL7558999 0.79 TACR1 (0.56) L3MBTL1HPGDKDM4EALDH1A1MAPK1
SCHEMBL7112383 0.78 PIK3CD (0.51) HPGDKDM4EALDH1A1MEN1KMT2A
SCHEMBL7111091 0.77 GPBAR1 (0.52)
SCHEMBL7110905 0.74 GPBAR1 (0.53) L3MBTL1HPGDALDH1A1MAPK1MEN1
SCHEMBL25045867 0.74 HPGD (0.60) HPGDKDM4EALDH1A1MAPK1MEN1
SCHEMBL22972337 0.74 MAPK1 (0.60) L3MBTL1HPGDKDM4EALDH1A1MAPK1
SCHEMBL27567270 0.73 PAK1 (0.43) ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1103546-B1 Process for preparation of pyridine derivatives HOFFMANN LA ROCHE (CH) 2003-10-22 EP disclosed
US-6479483-B2 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-11-12 US disclosed
US-20020091265-A1 4-phenyl-pyridine derivatives BOS MICHAEL (CA) 2002-07-11 US disclosed
US-6303790-B1 REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND HOFFMAN-LA ROCHE INC. 2001-10-16 US disclosed
US-6297375-B1 4-phenyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2001-10-02 US disclosed
EP-1103546-A1 Process for preparation of pyridine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091265-A1 4-phenyl-pyridine derivatives CBR1, CBR3, HCCS L3MBTL1 1978/4885HPGD 507/4885KDM4E 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.